In the News
Targeted Oncology
February 4, 2025
Marwan G. Fakih, MD, discussed the implications of the findings from the phase 2 study for patients with microsatellite stable metastatic colorectal cancer without liver metastases.
OncLive
February 3, 2025
Neoadjuvant botensilimab and balstilimab showed high MPR rates in MSS and MSI-H CRC, with no recurrences reported.
Medpage Today
January 27, 2025
An immunotherapy combination for advanced, highly mutated colorectal cancer (CRC) significantly slowed disease progression versus a single drug, according to a randomized study.
Cancer Network
January 27, 2025
The major pathologic response rate improved with extended time to surgery using botensilimab plus balstilimab in resectable colorectal cancer.